An update on the immunogenetics of idiopathic inflammatory myopathies: Major histocompatibility complex and beyond

Current Opinion in Rheumatology

Volumn 21, Issue 6, 2009, Pages 588-593

  Chinoy, Hector ^a   Lamb, Janine A ^a   Ollier, William Er ^a   Cooper, Robert G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Autoantibodies; Human leukocyte antigen; Myositis; Single nucleotide polymorphisms

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; HLA DPB1 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; JO 1 ANTIBODY; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TRANSCRIPTION FACTOR TAL1; TUMOR NECROSIS FACTOR ALPHA;

CELL INCLUSION; DISEASE PREDISPOSITION; GENETIC RISK; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOSITIS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; APOLIPOPROTEIN E4; CHILD; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HLA-DP ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOGENETIC PHENOMENA; IMMUNOGLOBULIN GM ALLOTYPES; MAJOR HISTOCOMPATIBILITY COMPLEX; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70349817084     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283315a22     Document Type: Review

References (39)

1. Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 1999; 107 (Suppl 5):693-700.
2. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
3. Chinoy H, Ollier WE, Cooper RG. Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies? Curr Opin Rheumatol 2004; 16:707-713.
4. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.
5. Ohanlon TP, Carrick DM, Arnett FC, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopatho-logic groups in Caucasians. Medicine (Baltimore) 2005; 84:338-349.
6. Ohanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85:111-127.
7. Ohanlon TP, Rider LG, Mamyrova G, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006; 54:3670-3681.
8. Chinoy H, Salway F, Fertig N, et al. Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology (Oxford) 2009; 48:591-592.
9. Cullen M, Perfetto SP, Klitz W, et al. High-resolution patterns of meiotic recombination across the human major histocompatibility complex. Am J Hum Genet 2002; 71:759-776.
10. Chinoy H, Payne D, Poulton KV, et al. HLA-DPB1 associations differ between DRB1 *03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. Rheumatology (in press).
11. Ohanlon TP, Rider LG, Schiffenbauer A, et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008; 58:3239-3246.
12. Rider LG, Shamim E, Okada S, et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999; 42:1285-1290.
13. Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002; 46:1885-1893.
14. Mamyrova G, Ohanlon TP, Sillers L, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008; 58:3941-3950.
15. Chinoy H, Platt H, Lamb JA, et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy in dependent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 2008; 58:3247-3254.
16. Vang T, Miletic AV, Bottini N, et al. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007; 40:453-461.
17. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37: 1317-1319.
18. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-4710.
19. Gregersen PK, Lee HS, Batliwalla F, et al. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006; 18:214-223.
20. Rider LG, Artlett CM, Foster CB, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000; 121:47-52.
21. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43:2368-2377.
22. Werth VP, Callen JP, Ang G, et al. Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 2002; 119:617-620.
23. Hassan AB, Nikitina-Zake L, Sanjeevi CB, et al. Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1 *03) with polymyositis and dermatomyositis. Arthritis Rheum 2004; 50:1013-1015.
24. Chinoy H, Salway F, John S, et al. Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology (Oxford) 2007; 46:1411-1416.
25. Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1 *0501 + children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168:4154-4163.
26. Chen YW, Shi R, Geraci N, et al. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol 2008; 9:43.
27. Hassan AB, Fathi M, Dastmalchi M, et al. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 2006; 27:62-68.
28. Jacob CO, Fronek Z, Lewis GD, et al. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990; 87:1233-1237.
29. Lio D, Candore G, Colombo A, et al. A genetically determined high setting of TNF-[alpha] influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity. Hum Immunol 2001; 62:705-713.
30. Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113:401-406.
31. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79:1056-1060.
32. Needham M, Mastaglia FL, Garlepp MJ. Genetics of inclusion-body myositis. Muscle Nerve 2007; 35:549-561.
33. Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003; 15:737-744.
34. Garlepp MJ, Tabarias H, van Bockxmeer FM, et al. Apolipoprotein E epsilon 4 in inclusion body myositis. Ann Neurol 1995; 38:957-959.
35. Needham M, Hooper A, James I, et al. Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal. Neuromuscul Disord 2008; 18:150-152.
36. Kruglyak L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 1999; 22:139-144.
37. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678.
38. Hindorff LA, Junkins HA, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. 2009. http://www.genome.gov/26525384.
39. Wedderburn LR, McHugh NJ, Chinoy H, et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007; 46:1786-1791.